What's in Kati Järvelä's pipeline?

Kati Järvelä has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Kati Järvelä's portfolio?

Top competitors by shared drug class: Grünenthal GmbH, Mundipharma Research GmbH & Co KG, Purdue Pharma LP.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kati-j-rvel.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kati Järvelä — Portfolio Competitive Intelligence Brief

Kati Järvelä pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Prolonged-release oxycodone/naloxone	Prolonged-release oxycodone/naloxone	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Grünenthal GmbH · 1 shared drug class
Mundipharma Research GmbH & Co KG · 1 shared drug class
Purdue Pharma LP · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kati Järvelä:

Cite this brief

Drug Landscape (2026). Kati Järvelä — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kati-j-rvel. Accessed 2026-05-16.